Back to search

Article

Neutralizing SARS-CoV-2 Antibody Response to 1st Dose of Astrazeneca-Oxford AZD1222 Vaccine Among Health Workers in North-Central Nigeria

2021-08-25

Abstract excerpt

Speed is an effective catalyst that can differentiate a time of war from other times. Thus, in a global record time of 11 months, the leading COVID-19 vaccine manufacturers completed the first COVID-19 vaccines. However, curbing the epidemic of anti-vaxxers has not been so easy globally. The world, particularly, in Africa has been largely influenced by the myths and conspiracy theories dissuading the public from a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e109ca32-7845-51f9-b7e8-35c54d21ee7c
DOI
10.2139/ssrn.3911105
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Neutralizing SARS-CoV-2 Antibody Response to 1st Dose of Astrazeneca-Oxford AZD1222 Vaccine Among Health Workers in North-Central NigeriaDOI 10.2139/ssrn.3911105
Antibody Responses After Oxford Astrazeneca (Covishield) Vaccine Among Healthcare Workers in Dhaka Medical College, Dhaka, BangladeshSemantic proximity
Antibody responses to AZD1222 vaccination in West AfricaSemantic proximity
Increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: an update from the COV-AD studySemantic proximity
Determinants of antibody responses to two doses of ChAdOx1 nCoV-19 or BNT162b2 and a subsequent booster dose of BNT162b2 or mRNA-1273: population-based cohort study (COVIDENCE UK)Semantic proximity
Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in Congolese individualsSemantic proximity
Dynamic Antibody Response in SARS-CoV-2 Infected Patients and COVID-19 Vaccine Recipients, and Vaccine Effectiveness in Comorbid and Multimorbid Patients​Semantic proximity
Determinants of Antibody Responses to Two Doses of ChAdOx1 nCoV-19 or Bnt162b2 and a Subsequent Booster Dose of BNT162b2 or mRNA-1273: Population-Based Cohort Study (COVIDENCE UK)Semantic proximity
Absence of Anti-RBD Antibodies in SARS-COV-2 Infected or Naive Individuals Prior to Vaccination With CoronaVac Leads to Short Protection of Only Four Months DurationSemantic proximity
Safety and Immunogenicity of Fractional Doses of COVID-19 Vaccines among Nigerian Adults- A Randomised Non-Inferiority trialSemantic proximity
Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a TrialSemantic proximity
SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings From The COV-AD StudySemantic proximity
Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using two-dose primary protocol in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow upSemantic proximity
Select a neighboring publication to make it the new centre.